	US 11,883,405 B2
	Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
Marguérite Mascha Mensonides-Harsema, Houston, TX (US); Charlott Brunmark, Flyinge (SE); and Karin von Wachenfeldt, Lund (SE)
Assigned to AMPLIO PHARMA AB, Lund (SE)
Appl. No. 16/617,763
Filed by Amplio Pharma AB, Lund (SE)
PCT Filed May 31, 2018, PCT No. PCT/EP2018/064322 § 371(c)(1), (2) Date Nov. 27, 2019, PCT Pub. No. WO2018/220101, PCT Pub. Date Dec. 6, 2018.
Claims priority of application No. 1750688-2 (SE), filed on May 31, 2017.
Prior Publication US 2020/0101074 A1, Apr. 2, 2020
Int. Cl. A61K 31/529 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/7048 (2006.01); A61P 19/02 (2006.01); A61K 31/519 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 9/20 (2013.01); A61K 31/7048 (2013.01); A61P 19/02 (2018.01)]

17 Claims

1. An immediate release pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof ranging from 5 to 100 mg, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof ranging from 5 to 250 mg, and optionally one or more pharmaceutically acceptable excipients, carriers, or diluents, wherein the ratio of novobiocin to methotrexate in the composition ranges from 0.05 to 20 malar equivalents and the immediate release pharmaceutical composition is in a form suitable for administration to a human subject.